BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 4, 2025
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Follow-on offerings of biopharma companies in January 2020

Jan. 31, 2020
Follow-ons completed by biopharma companies, including: Adaptimmune, Albireo, Alector, Apellis, Applied, Aptinyx, Autolus, Biohaven, Blueprint Medicines, Catabasis, Concert, DBV, Denali, Heat Biologics, Hutchison China Meditech, Immunogen, Intelgenx, Intra-Cellular, Matinas, Mirati, Mirum, Nanoviricides, Osmotica, Trillium, Xenon, Zai Lab, Zymeworks.
Read More

Other financings of public biotechnology companies in January 2020

Jan. 31, 2020
Private placements and other private financings of public biopharma companies, including: Advaxis, Algernon, Alimera, Armata, Azurrx, Bergenbio, Biocurepharm Korea, Bonus Biogroup, Cellect, Chemocentryx, Cidara, Clovis, Cocrystal, Edesa, Epizyme, Eyegate, Genprex, Helix, Hemogenyx, Hemostemix, Infinity, Iterum, Kamada, Leap, Lineage Cell, Novus, Noxxon, Promis, Puretech, Saniona, Sellas, Seneca, Spero, Tetra, Tetraphase, Titan, Vaxil, Vitro, Wize.
Read More

Venture capital and other private biopharma financings in January 2020

Jan. 31, 2020
Venture capital and other private financings of private biopharma companies, including: Adagene, Aegle, Agilvax, Airway, Alderaan, Aligos, Arpeggio, Biograil, Biointervene, Bionetix, Calidi, Cerebral, Codagenix, Domain, Empirico, Eqrx, Fusion, Genesen, Heparegenix, Idbydna, Immuneering, Jasper, Kyverna, Lyra, Nference, Northsea, Seekyo, Tarsus, Treadwell, Tscan, Tyra, Urania, Vectivbio.
Read More

Milestone payments from corporate partners in January 2020

Jan. 31, 2020
Triggered milestone payments disclosed by biopharma companies, including: BMS, Evotec, Gilead, Newsoara, Roche, Scholar Rock, Seattle Genetics, Zenith Epigenetics.
Read More

BioWorld and Nasdaq stock indices

Jan. 31, 2020
These graphs compare the performance of the biotech stocks for all of 2019 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.
Read More
Arrows pointing upward

Biggest gainers and losers for the week of Jan. 27-31, 2020

Jan. 31, 2020
The top 10 biopharma stock gainers and losers for the week, including: Acceleron, Amgen, Beigene, Biontech, Cortexyme, Precision, Reata, Syndax, United, Vir.
Read More

Med-tech gainers and losers for Jan. 27-31, 2020

Jan. 31, 2020
The top 10 med-tech stock gainers and losers for the week.
Read More
U.S.-China capsule

Trade deal could help China’s biotech upgrade, if honored

Jan. 28, 2020
By Jihyun Kim and Elise Mak
HONG KONG and BEIJING – Not just multinational players but domestic Chinese pharmaceutical companies are poised to benefit from China’s promise under a phase one trade deal with the U.S. to better protect intellectual property (IP), even if question marks remain around how the deal will be enforced. The move is in line with China's ambition to strengthen IP rights protection and upgrade the approach to innovation of its pharmaceutical and biotech industries.
Read More
DNA illustration

Significant year of growth for regenerative medicine sector

Jan. 28, 2020
By Peter Winter
According to Janet Lambert, CEO of the Alliance for Regenerative Medicine (ARM), in her delivery of the international advocacy group’s state of the industry briefing at Biotech Showcase in San Francisco, 2019 proved to be a significant year of growth for the regenerative medicine sector.
Read More
Petri dish and capsules
‘Wake-up call’

Current R&D investments insufficient to stem rising AMR tide

Jan. 28, 2020
By Peter Winter
Adding further evidence about the global threat of the increase of antimicrobial-resistant (AMR) infections and dearth of new antibiotics to treat those conditions, Thomas Cueni, chair of the AMR Industry Alliance, said the findings from the alliance’s newly released report are “a wake-up call” as they estimate current investments in AMR-relevant R&D are not enough to sustain a viable pipeline that will be needed to combat infectious diseases globally.
Read More
Previous 1 2 … 237 238 239 240 241 242 243 244 245 … 261 262 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • Handshake with DNA, molecules

    Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

    BioWorld
    Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • 3D illustration of pancreatic cancer

    ASCO 2025: Verastem has positive cancer data but stock sags

    BioWorld
    New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing